Skip to main content
. 2023 May 12;4(6):100525. doi: 10.1016/j.jtocrr.2023.100525

Figure 1.

Figure 1

AXL expression levels are negatively correlated with the efficacy of EGFR TKI treatment: clinical case. (A) A 67-year-old man underwent left upper lobectomy for localized NSCLC (pT2aN0M0) in January 2021. Postoperative recurrence was diagnosed in July 2021 during postoperative adjuvant chemotherapy with S-1. A CT scan and left thoracentesis were performed on the day before initiation of erlotinib plus ramucirumab. A CT scan was performed 9 days after initiation of treatment, and the treatment was discontinued. The patient died 15 days after initiation of the treatment. (B) CT scans taken before initiation of the treatment and those taken 9 days after initiation of the treatment. (C) The AXL mRNA expression levels of autopsy specimens measured by qPCR. (D) The EGFR-L858R–mutated mRNA expression levels of autopsy specimens measured by qPCR. (E) The AXL mRNA expression levels divided by the EGFR-L858R–mutated mRNA expression levels. CT, computed tomography; qPCR, quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor.